Analysis reveals discrepancies in reporting clinical uncertainties in cancer drugs by NCCN and journal publications.
This study assesses the reporting by journal publications and National Comprehensive Cancer Network (NCCN) guidelines of clinical uncertainties identified by the US Food and Drug Administration’s (FDA) Benefit-Risk Framework pertaining to cancer drugs approved in 2019-2022.
No takes yet. Share an insight, caveat, or question.
Cherla et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: